RE: £50mln target28 Apr 2026 08:33
Look to future not the past ( as results were)
£6.6mln Placing and acquisition of March 2026 cleared now and passed by the GM
Fully diluted market cap of £12mln with over £6mln in cash
CEO and other.TR1.holders added a.signicamt amount and as of 14th April
Beaumont-Dark family 150,000,000 15.11%
Dowgate Capital / Onward Opportunities 144,488,000 14.55%
Simon Deacon 96,203,613 9.69% (CEO)
Premier Miton 70,000,000 7.05%
Oberon Investments 50,000,000 5.04%
Dr Graham Cooley 41,500,000 4.18% (Non exec chair)
Puma Investment Management 30,000,000 3.02%
LSTH Trustee 8,900,000 0.90%
LST recently converted £0.3mlm of it's.£35 million AgTech pipeline.
April 9th Rns highlighted the Government's Building Safety Regulator ("BSR") Strategic Plan ("Plan") for 2026-2027, which vows to cut delays and expediate cladding remediation schemes.
Positive implications for LST's Passive Fire Protection Division which specialises in fire remediation solutions including the patented Injectaclad cavity fire barrier remediation and there is build-up of a substantial pipeline of contracted and near-term projects awaiting regulatory sign-off.
Shore.Capital Broker note early April
PFP (Passive Fire Protection) the division driving our investment case:
Since its acquisition by LST in late 2023, PFP grew revenues and profits rapidly as an installer of Injectcalad before seeing a slow down due to Building Safety Regulator delays in the latter part of FY25F. Injectaclad has a practical and cost-effective solution to rectify non-compliant public and private buildings to meet fire safety regulations by 2029 - a challenge addressed by a £6.1bn allocation from the UK Government in 2021. This innovative solution is an attractive alternative to removing external façades and installing traditional fire barriers. We consider LST’s recent acquisition of Injectaclad as transformational as highlighted in our recent initiation note given the regulatory drivers, we believe that PFP is well-positioned to convert its latest reported c.£24m sales pipeline in FY26F. The Injectaclad acquisition is likely to significantly boost the sales pipeline and potentially increase/protect gross margins.
Valuation:
We used a DCF analysis focused only on PFP hitting the £20m revenue target to derive a value of 4.6p per share on our best-case scenario. Given LST’s cash flow characteristics, we still believe that this could prove highly conservative and today announcement is a further positive step in the right direction. This would especially be the case if AGT sees significant sales traction towards management’s five-year target, the DCF value per share could be multiples of 4.6p.